Nasonov_E.L._Антифосфолипидный синдром_(Literra,2004)-1

1.Reddel SW, Krilis SA. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Imunol 1999; 6: 775—782.

2.Roubey, RA. Immunology of the antiphospho lipid antibody syndrome. Arthritis Rheum 1996;

39:1444.

3.Triplet DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126: 1424—1429.

4.Galli M, Barbui T. Prevalence of different antiphospholipid antibodies in systemic lupus ery thematosus and their relationship with the antiphospholipid syndrome. Clin Chem 2001; 47: 985—987.

5.Strandberg Pederrsen N, Orum O, Mouritsen S. Enzyme linked immunosorbent assay for detection of antibodies to the veneral disease research laboratory (VDRL) antigen in syphilis. J Clin Microbiol 1987; 25: 1711—1716.

6.Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: Immunologic and clinical aspects. Semin Arthritis Rheum 1990; 20: 81.

7.Triplett DA, Brandt JT, Musgrave KA. Relationship between lupus anticoagulants and

antibodies to phospholipids. JAMA 1988; 259: 550.

8.Hanly JG, Kandiah D, Kouts S. et al. Detect ion of "antiphospholipid antibodies" using a chro mogenic assay thrombin generation. Lupus 1998;

7:219 (abstract).

9.Pierangeli SS, M. SLK Silva, Harris EN. An antiphospholipid workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998; 25:156—160.

10.Harris EN. The second intenational anti cardiolipin standartisation workshop. The Kingston antiphospholipid study (KAPS) group. Am J Clin Pathol 1990; 94: 476—484.

11.Александрова ЕН, Насонов ЕЛ, Ковалев В.Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови. Клиническая ревматол. 1995; 4: 35—39.

12.Tincani A, Balestrieri G, Allegri F. et al. Overview on anticardiolipin ELISA standartiza tion. J Autoimmunity 2000; 15: 195—197.

13.Alarcon Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphos

pholipid syndrome in systemic lupus erythemato sus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353—365.

14.Escalante A, Brey RL, Mitchell BD, et al. Accuracy of anticardiolipin antibodies in identify ing a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;

98:559—565.

15.Wasmuth JC, Minarro DO, Homrighausen A, et al. Phoshpholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifesta tions. Clin Chem 2002; 48: 1004—1010.

16.Musial J, Swadzba J, Motyl A, et al. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003; 30: 723—730.

17.Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The working group on methodologies in haemostasis from the GEHT (groupe d'Etudes sur le hemosta sis et la thrombose). Thromb Haemostasis 1995;

73:444—452.

18.Andrian MA, Colonna F, Morio F, et al. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2 glycoprotein 1. Rheumatology (Oxford). 2004; 43:181—185.

19.McNeil HP, Chesterman CN, Krilis SA, et al. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193—280.

20.Boffa MC, Berard M, Sugi T, et al. Anti phosphatidulethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA II Kininigen reactivity. J Rheumatol 1996; 23: 1375—1379.

21.Harris EN, Pierangeli SS. "Equivocal" antiphospholipid syndrome. J Autoimmunity 2000; 15: 81—85.

22.Day HM, Thiagarajan P, Ahn C, et al. Antibodies to β2 glycoprotein I in systemic lupus erythehematosus and primary antiphospholipid syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheu matol 1998; 25: 667—674.

23.Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of anticardiolipin antibodies

defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885—3891.

24.Hasselaar P, Triplett DA, La Rue A, et al. Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA. J Rheumatol 1990; 17: 186—191.

25.Cabiedes J, Cabral AR, Alarcon Segovia D. Hidden antiphospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hipermolar buffers or phospholipase treatment. Eur J Rhumatol 1998; 28: 2108—2114.

26.Matsuda J, Saiton N, Gohchi K, et al. Distinguising β2 glycoprotein I dependent (sys temic lupus erithematosus type) and independent (syphilis type) anticardiolipin antibody witch tween 20. Br J Haematol 1993; 85: 799—802.

27.Arvieux J, Roussel B. Influence of Tween 20 on the detection of β2 glycoprotein I dependent anticardiolipin antibodies. Br J Haematol 1994;

87:443—444.

28.Cabral AR, Cabiedes J, Alarcon Segovia D. Tween 20 detaches cardiolipin from ELISA

plates and maker anticardiolipin antibodies undetectable regardless of the presence of β2 gly coprotein I. J Immunol Methods 1994; 175: 107—114.

29.Hunt JE, McNeil HB, Morgan GJ, et al. A phospholipid β2 glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75—81.

30.Arvieux J, Darnige L, Hachulla E, et al. Species specificity of anti β2 glycoprotein I auto antibodies and its relevance to anticardiolipin antibody quantitation. Thromb Haemostasis 1996; 75: 725—730.

31.McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are direct

ed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2 glycoprotein I (apoliprotein H). Proc Natl Acad Sci USA. 1990; 87: 4120—4124.

32.Roubey RA. Antigenic specifities of antiphos pholipid antibodies implications for clinical labo ratory testing and diagnosis of the antiphospho lipid syndrome. Lupus 1996; 5: 425—430.

33.McCarthy JM, Wagenknecht DR., McIntyre J.A. Activity of antiphospholipid antibody ELISA

temic lupus erythematosus. Ann Rheum Dis 1988;

47:286—290.

55.Tsutsumi A, Koike T, Ichikawa K, et al. IgG subclass distribution of anticardiolipin antibody in patients with systemic lupus erythematosus. J Rheumatology 1988; 15: 1764—1767.

56.Loizou S, Cofiner C, Weetman AP, Walport MJ. Immunoglobulin class and IgG subclass dis tribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 1992; 90: 434— 439.

57.Samaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclass. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40: 1998—2006.

58.Samarkos M, Davies KA, Gordon C, et al. IgG subclass distribution of antibodies against β2 GPI and cardiolipin in patients with systemic lupus erythematosus and primary antiphospho lipid syndrome, and their clinical associations. Rheumatology 2001; 40: 1026—1032.

59.Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2 subclass resriction of anti β2 glycopro tein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310—315.

60.Arveux J, Darnige L, Caron C, et al. Deve lopment of an ELISA for autoantibodies to pro thrombin showing their orevalence in patients with lupus anticoagulant. Thromb Haemost 1995;

74:1120—1125.

61.Galli M, Beretta G, Daldossi M, et al. Different anticoagulant and immunological prop erties anf anti prothrombin antibodies in patients with antiphospholipid antibodies. 1997; 77: 486— 491.

62.Amengual O, Atsuni T, Koike T. Specifi cities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003; 48: 886—895.

63.Galli M, Barbui T. Antiprothrombin anti bodies: detection and clinical significance. Blood 1999; 93: 2149—2157.

64.Horbach D, van Oort E, Derksen R, de Groot P. The contribution of anti prothrombin antibodies to lupus anticoagulant activity dis crimination between functional and non func tional anti prothrombin antibodies. Thromb Haemost 1998; 79: 790—5.

65.Akimoto T, Akama T, Kono I, Sumida T. Relationship between clinical feature and binding domains of anti prothrombon autoantibodies in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 1999; 8: 761—766.

66.Nojima J, Kuratsune H, Suehisa E, et al.

Association between the prevalence of antibodies to β2 glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus anr thrombotic and throm bocytopenic complications. Clin Chem 2001; 47: 1008—1015.

67.Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus antico agulant in systemic lupus erythematosus (SLE) and non SLE disorders. Ann Intern Med 1990;

112:682.

68.Abu Shakra, M, Gladman, D, Urowitz, MB, Farewell, V. Anticardiolipin antibodies in systemic lupus erythematosus: Clinical and labo ratory correlations. Am J Med 1995; 99: 624.

69.Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti beta2GPI antibodies in a large series of European patients with sys temic lupus erythematosus. Prevalence and clini cal associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999; 28: 344.

70.Nasonov EL, Kovalev VYu, Alekberova ZS, Soloviev SK. Prediction of thrombosis in patients with systemic lupus erythematosus: the role of antibodies to cardiolipin. Sov Arch Intern Med 1992; 64: 348—353.

71.Neville C, Rauch J, Kassis J, et al. Thrombotic risk in partients with high titre anti cardiolipin and multiple antibodies. Thromb Haemost 2003; 90: 108.

72.Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immu nologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019.

73.Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulant are stronger risk factor for thrombosis than anticatdiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827—1832.

74.Александрова ЕН, Новиков АА, Решет

няк ТМ, Клюквина НГ, Решетняк ДВ, Насо нов Е.Л. Антитела к β2 ГП1 и антитела к кардиолипину при антифосфолипидном синд роме: анализ чувствительности и специфич ности. Клин. медицина, 2003; 9: 25—31.

75.Amengual O, Atsumi T, Khamashta MA,

Koike T, Huges GRV. Specificity of ELISA for antibody to β2 glicoprotein I in patients with antiphospholipid sindrome. Br J Rheumatol 1996;

35:1239—1243.

76.Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmunity 2000; 15: 163—172.

77.Решетняк ТМ, Дерксен РВ, Алекберова ЗС, и др. Антитела к β2 гликопртеину I при системной красной волчанке: новый лаборо торный маркер антифосфолипидного синдро ма. Клин. медицина, 1998; 3: 36—40.

78.Martinuzzo ME, Forastiero RR, Carreras LO. Anti β2 glycoprotein I antibodies: detection and association with trombosis Br J Haematol 1995; 89: 397—405.

79.Gomez Pacheco L, Villa AR, Drencard C,

Cabiedes J, Cabral AR, Alarcon Segovia D. Serum anti β2 glycoprotein I and anticardiolipin antibodies during trombosis in systemic lupus ery tematosus patients. Am J Med 1999; 106: 417— 423.

80.Long AA, Ginsberg JS, Brill Edwards P, Johnston M, Turner C, Deuburg JA, Bensen WG, Cividino A, Andrew M, Hirsh J. The realation ship of antiphospholipid antibodies to throm boembolic disease in systemic lupus erytematosus: a cross sectional study. Thromb Haemost 1991;

66:520—525.

81.Wahl DG, Guillemin F, de Maistre E, Peret C., Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus A meta analisis. Lupus 1997; 6: 464—473.

82.Roubey RAS, Maldonado MA, Byrd SN.

Comparison of an enzimelinked immunosorbent assay for antibodies to β2 glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996; 39: 1606—1607.

83.Detkova D, Gil Aguado A, Lavilla P et al. Do antibodies to β2 glycoprotein I contribute to

the better characterization of the antiphospholipid syndrome? Lupus 1999; 8: 430 438.

84.Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of the antiphospholipid syndrome a proposal for use of laboratory tests. Lupus 1998; 7(Suppl); S.144—148.

85.Najmey SS, Keil B, Adib DY, De Bary VA. The association of antibodies to β2 glicoprotein I with the antiphospholipid syndrome: A Meta analysis. Ann Clin Lab Science 1997; 27: 41—46

86.Cabiedes J, Cabral A, Alarcon Segovia D. Clinical manifestation of the antiphospholipid

syndrome in patients with systemic lupus erytem atosus associate more strongly with anti β2 glyco protein I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899—1906.

87.Picillo U, Marcilis MR, Italiano G. Anti bodies to β2 glycoprotein I in anticardiolipin neg ative patients. J Rheumatol 1998; 25: 1440— 1442.

88.Loizou S, Byron MA, Englert HJ, et al. Association of quantitative anticardiolipin anti body levels with fetal loss and time of loss in sys temic lupus erythematosus. Q J Med 1988; 68:525

89.Geis W, Branch DW. Obstetric implications of antiphospholipid antibodies: pregnancy loss and other complications. Clin Obstet Gynecol 2001; 44: 2.

90.Lockwood CJ, Schur PH. Clinical manifes tations and diagnosis of the antiphospholipid syn drome in pregnancy UpToDate 2003; 11.3.

91.Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489.

92.Kupferminc MJ. Thrombophilia and preg nancy. Reproductive Biol Endocrinol 2003; 1: 111.

93.Branch DW, Scott JR, Kochenour NK, et al. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322.

94.Branch DW, Khamashta MA. Antiphos pholipid syndrome: obstetric diagnosis, manage ment, and controversies. Obstet Gynecol 2003;

101:1333.

95.Lynch A, Byers T, Emlen W, et al. Associ ation of antibodies to beta(2) glycoprotein 1 with pregnancy loss and pregnancy induced hyperten

sion: A prospective study in low risk pregnancy. Obstet Gynecol 1999; 93: 193.

96.Lee RM, Emlen, W, Scott, JR, et al. Anti beta2 glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol 1999; 181: 642.

97.Yasuda M, Takakuwa, K, Tokunaga, A, Tanaka, K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555.

98.Lima F, Khamashta MA, Buchanan, NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheu matol 1996; 14:131.

99.Branch DW, Silver, RM Blackwell, JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80: 614.

100.Schei, B, Ostensen, M, Moen, T, et al. Can maternal antiphospholipid antibodies predict the birth of a small for gestational age child? Acta Obstet Gynecol Scand 1995; 74: 425.

101.Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26.

102.Montaruli B, Borchiellini A, Tamponi G, et al. Factor V Arg506 >Gln mutation in patients with antiphospholipid antibodies. Lupus 1996; 5: 303.

103.Silver RM, Draper ML, Scott JR, et al. Clinical consequences of antiphospholipid anti bodies: An historic cohort study. Obstet Gynecol 1994; 83: 372.

104.Lynch A, Marlar R, Murphy J, et al. Anti phospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994; 120: 470.

105.Pattison NS, Chamley LW, McKay EJ, et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909.

106.Alsulyman OM, Castro, MA, Zuckerman, E, et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphos pholipid syndrome. Obstet Gynecol 1996; 88: 644.

107.Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001; 184: 825.

108.American College of Obstetricians and Gynecologists. Antiphospholipid syndrome. ACOG educational bulletin 244. ACOG 1998; Washington, DC.

109.Galli M. Should we include anti pro thrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000;

15:101—105.

110.Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid binding plasma proteins and occurrence of thrombosis in patients with systemic lupus ery thematosus. Clin Immunol Immunopathol 1996;

80:16—22.

111.D'Angelo A, Safa O, Crippa L, Garlando A, Sabbadini M, Vigano' D'Angelo S. Relationship of lupus anticoagulant, anticardi olipin, anti beta2 GPI and anti prothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA syn drome. Thromb Haemost 1997; 78: 967—8.

112.Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti prothrombin antibodies in patients with antiphospholipid anti bodies. Thromb Haemost 1997; 77: 486—91.

113.Swadzba J, De Clerck L, Stevens W, Bridts C, van Cotthem K, Musial J, et al. Anti cardiolipin, anti beta(2) glycoprotein I, antipro thrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997; 24: 1710—5.

114.Bertolaccini M, Atsumi T, Khamashta M, Amengual O, Hughes G. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 1104—8.

115.Guerin J, Smith O, White B, Sweetman G, Feighery C, Jackson J. Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br J Haematol 1998; 102: 896—902.

116.Inanc M, Donohoe S, Ravirajan C, Radway Bright E, Mackie I, Machin S, et al. Anti beta2 glycoprotein I, anti prothrombin and anticardiolipin antibodies in a longitudinal study

of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1998; 37: 1089—94.

117.Sorice M, Pittoni V, Circella A, et al. Anti prothrombin but not pure anticardiolipin antibod ies are associated with the clinical features of the antiphospholipid antibodies syndrome. Thromb Haemost 1998; 80: 713—715.

118.Lakos G, Kiss E, Regeczy N, et al. Anti prothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune disease. J Rheumatol 2000; 27: 924—929.

119.Munoz Rodriguez F, Reverter J, Font J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with sys temic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000; 85: 632—637.

120.Nojima J, Kuratsune H, Suehisa E, et al. Anti prothrombin antibodies combined with lupus

anti coagulant activity is an assensial risk factor for venous thromboembolism in patients with sys temic lupus erythematosus. Br J Haematol 2001;

114:647—654.

121.Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phos phatidylserine prothrombin complex with mani festations of the antiphospholipid syndrome and with the oresence of lupus anticoagulant. Arthritis Rheum 2000; 43: 1982—1983.

122.Калашникова ЛА, Чапман Н, Насонов ЕЛ, и соавт. Новые клинические имммуноло гические данные о синдроме Снеддона. Клин. медицина, 1998; 6: 34—37.

123.Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non thrombotic, non autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstretricians and Haematologist Study — NOHA. Thrombo Haemost 2000; 84: 228—236.